Evidence map›Paper›PMID 34277989›Full record

ArticleEndocrinology, diabetes & metabolism2021

The Effect of ThyroidߚStimulating Hormone on Stage of Differentiated Thyroid Carcinoma.

Laya Soleimanisardoo, Mohsen Rouhani, Fatemeh Soleymani Sardoo, Mohammad Hossein Gozashti

Abstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Laya SoleimanisardooEndocrine and Metabolism Research Center Institute of Basic and Clinical Physiology Sciences Kerman University of Medical Sciences Kerman Iran.ORCID 0000-0001-7870-2887
Mohsen RouhaniEndocrine and Metabolism Research Center Institute of Basic and Clinical Physiology Sciences Kerman University of Medical Sciences Kerman Iran.
Fatemeh Soleymani SardooPathology and Stem Cell Research Center Afzalipour Hospital Kerman University of Medical Sciences Kerman Iran.
Mohammad Hossein GozashtiEndocrine and Metabolism Research Center Institute of Basic and Clinical Physiology Sciences Kerman University of Medical Sciences Kerman Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThyroid cancer is the most common endocrine malignancy, and it has the fastest increase rate in incidence in both sexes, with a yearly increase of 3% over the last decade. Thyroid-stimulating hormone (TSH) is the main driver for the thyroid gland to produce thyroid hormone. The main purpose of this study was to assess the relationship between serum TSH level and the stage of malignancy in patients with differentiated thyroid cancer.

methodsThis cross-sectional study was performed on 77 patients with thyroid cancer. The demographic characteristics, TSH level and stage of malignancy were recorded for all patients in the data collection form. The data analysis was conducted by descriptive statistics using SPSS 20.0 software.

resultsThe results show a significant relationship (

conclusionsAccording to the results of this study, serum TSH level can be considered as a predictor of the stage of differentiated thyroid cancer. Therefore, it can be used to predict the likelihood of cancer and improve the outcome and extent of thyroidectomy in patients with thyroid cancer.

Indexed as

AdenocarcinomaThyroid NeoplasmsCross-Sectional StudiesFemaleHumansMaleThyroidectomyThyrotropinThyrotropindifferentiated thyroid cancerstage of malignancyTSH level

Identifiers

PMID34277989
PMCPMC8279600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.